Investors & Media
Company Overview
View All
LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.

Featured News
Scientist Look to Grow 'Mini Livers' for Patients with Organ Damage
After decades of overblown expectation, regenerative medicine looks ready to take a step further
Read More 




